Universität zu Köln

Wennhold, Kerstin ORCID: 0000-0001-5539-7226, Weber, Tanja M., Klein-Gonzalez, Nela, Thelen, Martin ORCID: 0000-0002-2785-9726, Garcia-Marquez, Maria, Chakupurakal, Geothy, Fiedler, Anne, Schloesser, Hans A., Fischer, Rieke, Theurich, Sebastian ORCID: 0000-0001-5706-8258, Shimabukuro-Vornhagen, Alexander and von Bergwelt-Baildon, Michael (2017). CD40-activated B cells induce anti-tumor immunity in vivo. Oncotarget, 8 (17). S. 27740 - 27754. ORCHARD PARK: IMPACT JOURNALS LLC. ISSN 1949-2553

Full text not available from this repository.

Abstract

The introduction of checkpoint inhibitors represents a major advance in cancer immunotherapy. Some studies on checkpoint inhibition demonstrate that combinatorial immunotherapies with secondary drivers of anti-tumor immunity provide beneficial effects for patients that do not show a strong endogenous immune response. CD40-activated B cells ( CD40B cells) are potent antigen presenting cells by activating and expanding naive and memory CD4(+) and CD8(+) and homing to the secondary lymphoid organs. In contrast to dendritic cells, the generation of highly pure CD40B cells is simple and time efficient and they can be expanded almost limitlessly from small blood samples of cancer patients. Here, we show that the vaccination with antigen-loaded CD40B cells induces a specific T-cell response in vivo comparable to that of dendritic cells. Moreover, we identify vaccination parameters, including injection route, cell dose and vaccination repetitions to optimize immunization and demonstrate that application of CD40B cells is safe in terms of toxicity in the recipient. We furthermore show that preventive immunization of tumor-bearing mice with tumor antigen-pulsed CD40B cells induces a protective anti-tumor immunity against B16. F10 melanomas and E.G7 lymphomas leading to reduced tumor growth. These results and our straightforward method of CD40B-cell generation underline the potential of CD40B cells for cancer immunotherapy.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Wennhold, Kerstin UNSPECIFIED orcid.org/0000-0001-5539-7226 UNSPECIFIED Weber, Tanja M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Klein-Gonzalez, Nela UNSPECIFIED UNSPECIFIED UNSPECIFIED Thelen, Martin UNSPECIFIED orcid.org/0000-0002-2785-9726 UNSPECIFIED Garcia-Marquez, Maria UNSPECIFIED UNSPECIFIED UNSPECIFIED Chakupurakal, Geothy UNSPECIFIED UNSPECIFIED UNSPECIFIED Fiedler, Anne UNSPECIFIED UNSPECIFIED UNSPECIFIED Schloesser, Hans A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Fischer, Rieke UNSPECIFIED UNSPECIFIED UNSPECIFIED Theurich, Sebastian UNSPECIFIED orcid.org/0000-0001-5706-8258 UNSPECIFIED Shimabukuro-Vornhagen, Alexander UNSPECIFIED UNSPECIFIED UNSPECIFIED von Bergwelt-Baildon, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-233709
DOI:	10.18632/oncotarget.7720
Journal or Publication Title:	Oncotarget
Volume:	8
Number:	17
Page Range:	S. 27740 - 27754
Date:	2017
Publisher:	IMPACT JOURNALS LLC
Place of Publication:	ORCHARD PARK
ISSN:	1949-2553
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language ANTIGEN-PRESENTING CELLS; TRANSFECTED DENDRITIC CELLS; T-CELLS; PROSTATE-CANCER; TUMOR-ANTIGENS; RESPONSES; IMMUNOTHERAPY; CARCINOMA; VACCINE; CD8(+) Multiple languages Oncology; Cell Biology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/23370